Mark G. Jones

7.7k total citations · 3 hit papers
70 papers, 3.3k citations indexed

About

Mark G. Jones is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Mark G. Jones has authored 70 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 17 papers in Physiology and 8 papers in Molecular Biology. Recurrent topics in Mark G. Jones's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (32 papers), Sarcoidosis and Beryllium Toxicity Research (14 papers) and Medical Imaging and Pathology Studies (11 papers). Mark G. Jones is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (32 papers), Sarcoidosis and Beryllium Toxicity Research (14 papers) and Medical Imaging and Pathology Studies (11 papers). Mark G. Jones collaborates with scholars based in United Kingdom, Italy and United States. Mark G. Jones's co-authors include Luca Richeldi, Harold R. Collard, Yihua Wang, Donna E. Davies, Joyce Lee, Paolo Spagnolo, Toby M. Maher, Christopher J. Ryerson, Argyrios Tzouvelekis and Jonathan A. Kropski and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Circulation.

In The Last Decade

Mark G. Jones

67 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Idiopathic pulmonary fibrosis

2017 1.4k citations Luca Richeldi, Mark G. Jones et al. profile →
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

2021 433 citations Yilu Zhou, Mark G. Jones et al. profile →
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development

2020 392 citations Mark G. Jones, Toby M. Maher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark G. Jones United Kingdom	20	2.3k	608	420	397	273	70	3.3k
Rosanna Vaschetto Italy	28	1.4k 0.6×	380 0.6×	188 0.4×	131 0.3×	191 0.7×	88	2.4k
Kenji Tsushima Japan	27	1.3k 0.6×	438 0.7×	129 0.3×	290 0.7×	481 1.8×	118	2.6k
Mark E. Wylam United States	26	1.5k 0.7×	406 0.7×	102 0.2×	772 1.9×	463 1.7×	74	3.0k
Nazia Chaudhuri United Kingdom	24	2.0k 0.9×	242 0.4×	93 0.2×	572 1.4×	285 1.0×	100	2.7k
Giuseppe Francesco Sferrazza Papa Italy	32	803 0.3×	397 0.7×	259 0.6×	222 0.6×	495 1.8×	132	3.5k
Peter I. Bonta Netherlands	27	946 0.4×	349 0.6×	405 1.0×	456 1.1×	219 0.8×	115	3.1k
Mario Santini Italy	27	1.3k 0.6×	400 0.7×	189 0.5×	276 0.7×	173 0.6×	217	2.6k
Francesco Facciolo Italy	34	2.2k 0.9×	530 0.9×	344 0.8×	733 1.8×	396 1.5×	158	3.6k
Lixin Zhou China	26	618 0.3×	574 0.9×	565 1.3×	120 0.3×	665 2.4×	146	2.7k
Christopher Wells United States	23	652 0.3×	1.3k 2.1×	258 0.6×	418 1.1×	266 1.0×	42	3.0k

Countries citing papers authored by Mark G. Jones

Since Specialization

Citations

This map shows the geographic impact of Mark G. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Jones more than expected).

Fields of papers citing papers by Mark G. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark G. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Jones. The network helps show where Mark G. Jones may publish in the future.

Co-authorship network of co-authors of Mark G. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Mark G. Jones. A scholar is included among the top collaborators of Mark G. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark G. Jones. Mark G. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sofia, Carmelo, Joseph A. Bell, Natasha H. C. Easton, et al.. (2025). Air pollution and alveolar health. European Respiratory Review. 34(177). 240280–240280.

Bell, Joseph A., Natasha H. C. Easton, Matthew J. Cooper, et al.. (2025). Copper-enriched automotive brake wear particles perturb human alveolar cellular homeostasis. Particle and Fibre Toxicology. 22(1). 4–4. 4 indexed citations

Jones, Mark G., et al.. (2025). Health Concerns of Youths From Historically Marginalized Communities During the Postacute Phase of COVID-19. JAMA Network Open. 8(3). e250837–e250837.

Milito, Cinzia, Davide Firinu, Nicholas Landini, et al.. (2024). Sarcoidosis versus Granulomatous and Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency: A Comparative Review. Biomedicines. 12(7). 1503–1503. 5 indexed citations

Jones, Mark G., et al.. (2023). Topological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis. Thorax. 78(7). 682–689. 3 indexed citations

Wallis, T, Magdalena Minnion, Anna Freeman, et al.. (2023). Individualised Exercise Training Enhances Antioxidant Buffering Capacity in Idiopathic Pulmonary Fibrosis. Antioxidants. 12(8). 1645–1645. 3 indexed citations

Humbert, María Victoria, C. Mirella Spalluto, Joseph A. Bell, et al.. (2022). Towards an artificial human lung: modelling organ-like complexity to aid mechanistic understanding. European Respiratory Journal. 60(6). 2200455–2200455. 7 indexed citations

Bell, Joseph A., Elizabeth R. Davies, Aurélie Fabre, et al.. (2022). Spatially resolved deconvolution of the fibrotic niche in lung fibrosis. Cell Reports. 40(7). 111230–111230. 29 indexed citations

Johnson, Peter, Artemios Karvounis, Haobijam Johnson Singh, et al.. (2021). Superresolved polarization-enhanced second-harmonic generation for direct imaging of nanoscale changes in collagen architecture. Optica. 8(5). 674–674. 22 indexed citations

10.

Tezera, Liku B., Andrés F. Vallejo, Milica Vukmirovic, et al.. (2021). Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies therapeutic targets. Journal of Clinical Investigation. 131(15). 22 indexed citations

11.

Zhao, An, Nesrin Moğulkoç, Iain Stewart, et al.. (2021). Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment. EClinicalMedicine. 38. 101009–101009. 9 indexed citations

12.

Brereton, Christopher J., T Wallis, Michelle Casey, et al.. (2020). Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes?. ERJ Open Research. 6(2). 120–2020. 18 indexed citations

13.

Conforti, Franco, Robert A. Ridley, Christopher J. Brereton, et al.. (2020). Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. Cell Death Discovery. 6(1). 54–54. 28 indexed citations

14.

Jones, Mark G., et al.. (2019). Contemporary Concise Review 2018: Interstitial lung disease. Respirology. 24(8). 809–816. 7 indexed citations

15.

Hill, Charlotte, Mark G. Jones, Donna E. Davies, & Yihua Wang. (2019). Epithelial-Mesenchymal Transition Contributes to Pulmonary Fibrosis via Aberrant Epithelial/Fibroblastic Cross-Talk. PubMed. 3(2). 31–35. 110 indexed citations

16.

Hill, Charlotte, Juanjuan Li, Dian Liu, et al.. (2019). Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. Cell Death and Disease. 10(8). 591–591. 127 indexed citations

17.

Fletcher, Sophie, Mark G. Jones, Elisabetta Renzoni, et al.. (2018). Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Research. 4(4). 49–2018. 26 indexed citations

18.

Sgalla, Giacomo, Simon Walsh, Sophie Fletcher, et al.. (2016). Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease. IRIS UNIMORE (University of Modena and Reggio Emilia). 193.

19.

Jones, Mark G., Sophie Fletcher, & Luca Richeldi. (2013). Idiopathic Pulmonary Fibrosis: Recent Trials and Current Drug Therapy. Respiration. 86(5). 353–363. 19 indexed citations

20.

Jones, Mark G., et al.. (2009). Cough, confusion and flaccid paralysis in a 46-year old man with left apical consolidation and ring-enhancing lesions on cerebral imaging. Thorax. 64(10). 862–862. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact